Tag: Commercialization
-
DOST-TAPI Eyes 5% Growth in IP Filings and Tech Adoption
Overview: DOST-TAPI’s Growth Targets for 2024 The Technology Application and Promotion Institute (TAPI) of the Department of Science and Technology (DOST) has unveiled an ambitious target for the year: a 5% increase in intellectual property (IP) filings and in the commercialization and adoption of technologies it supports. Announced during the agency’s 39th anniversary celebration, the…
-
Pony.ai Expands Robotaxi Commercialization With ATBB, Advancing Asset-Backed Growth
Strategic Partnership Accelerates Robotaxi Commercialization Beijing-based autonomous driving leader Pony.ai announced a strategic partnership with Beijing ATBB Travel & Express Service Co., Ltd., signaling a major step forward in the commercialization of robotaxi services. The collaboration aims to scale production-ready autonomous driving solutions and expand the deployment of robotaxis across transportation networks that ATBB operates,…
-
Precigen Expands Commercial Momentum for PAPZIMEOS at JPMorgan Conference
Precigen Highlights Commercial Momentum at the JPMorgan Healthcare Conference At the 44th Annual JPMorgan Healthcare Conference, Precigen underscored a pivotal shift: the company has moved decisively into commercial stage with PAPZIMEOS, the first-and-only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Since receiving U.S. approval in August 2025, Precigen has been actively scaling its…
-
Precigen Accelerates PAPZIMEOS Commercialization at 44th JP Morgan Conference, Driving Adoption for FDA-Approved RRP Therapy
Precigen Marks a New Era as a Commercial-Stage Biotech At the 44th Annual J.P. Morgan Healthcare Conference, Precigen showcased a pivotal shift from development-focused biotech to a commercial-stage company. The centerpiece of the presentation was PAPZIMEOS, the first-and-only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Since receiving U.S. approval in August 2025, Precigen…